ELSTREE, England, Oct. 30, 2019 /PRNewswire/ -- Masters Speciality Pharma ("Masters"), a UK-headquartered pharmaceutical company specialising in the global distribution of high-quality, life ...

Neuropad results correlated with neuropathy disability score (r = 0.450, ... (r = −0.271, P = 0.04). The Neuropad test detected clinically relevant neuropathy with a sensitivity of 85% ...

There is also no evidence to suggest that Neuropad is more effective than standard testing for diabetic peripheral neuropathy with a 10 g monofilament. ISBN: 978-1-4731-2948-1. Additional resources.

London, UK, 2nd October 2008 - Ark Therapeutics Group plc ("Ark" or the "Company") today announces that it has successfully achieved reimbursement from the UK NHS Business Services Authority for ...

The Masters team launched Neuropad at the Brazilian Congress of Diabetes held from the 16th – 18th October 2019 in Natal, Brazil. About Masters Speciality Pharma ...

Neuropad detects abnormal sweating in people with diabetes. But the clinical importance of this is poorly defined. There is insufficient evidence to support the use of Neuropad in people in whom 10 g ...

Elstree, 30 October 2019 – Masters Speciality Pharma (“Masters”), a UK-headquartered pharmaceutical company specialising in the global distribution of high-quality, life-changing medicines, today ...

ELSTREE, England, Oct. 30, 2019 /PRNewswire/ -- Masters Speciality Pharma ("Masters"), a UK-headquartered pharmaceutical company specialising in the global distribution of high-quality, life-changing ...